ASH 2021 | Novel therapies for patients with MCL after failed response to BTK inhibitors
Tycel Phillips
• 12 Dec 2021
In this video, Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, highlights some of the most promising therapies for patients with mantle cell lymphoma (MCL) following failed response to Bruton’s tyrosine kinase (BTK) inhibitor therapy. Dr Phillips draws focus on the major impact of chimeric antigen receptor T-cell (CAR-T) therapy, as well as the safety and efficacy of bispecific antibodies such as pirtobrutinib, and how these therapeutic options can improve future outcomes for patients with MCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
